Related Experiment Video
Updated: Oct 6, 2025

05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
452
Medication Errors in Overweight and Obese Pediatric Patients: A Narrative Review
Joint Commission Journal on Quality and Patient Safety
|January 20, 2022
Summary
Medication errors, including overdosing and underdosing, are more common in overweight and obese children. This review highlights a lack of evidence on pediatric medication safety, suggesting increased risk for these children.
Area of Science:
- Pediatric pharmacology
- Patient safety research
- Public health
Background:
- Childhood obesity is increasing healthcare utilization and medication prescriptions.
- The impact of obesity on medication errors in children is not well understood.
Purpose of the Study:
- To review the existing literature on the incidence and types of medication errors in overweight and obese children.
- To identify factors contributing to medication errors in this population.
Main Methods:
- Systematic literature search of MEDLINE, Embase, and Scopus databases up to December 2020.
- Inclusion of studies reporting medication errors in pediatric patients (≤ 18 years) who are overweight or obese.
- Methodologic quality assessment using GRADE criteria.
Main Results:
- Five studies met inclusion criteria, detailing dosing errors for antimicrobials, anesthetics, and paracetamol.
- Two comparative studies indicated higher rates of medication errors (over- and underdosing) in obese children.
- Identified causes include incorrect weight-based dosing, dosing strategies, and inappropriate use of age-based schemas.
Conclusions:
- There is a significant lack of patient safety evidence regarding medication use in overweight and obese children.
- Overweight and obese children may face a heightened risk of medication errors, though clinical significance requires further investigation.
Related Concept Videos
Drug Dosing: Obese Patients
8
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
8
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
6
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
6
Drug Dosing: Infants and Children
21
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
21
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
12
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
12
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
5
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
5
Pharmacokinetics in Pediatric Patients: Drug Metabolism
17
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
17

